KalVista Pharmaceuticals (KALV) Total Debt (2014 - 2016)

KalVista Pharmaceuticals has disclosed Total Debt across 3 years of filings, most recently posting $4.7 million for Q1 2016.

• Total Debt for Q1 2016 came in at $4.7 million, up 3.84% year-over-year; the trailing twelve-month figure through Mar 2016 was $4.7 million (up 3.84% YoY), and the FY2016 annual result was $127000.0, changed N/A from the prior year.
• Total Debt came in at $4.7 million for Q1 2016 at KalVista Pharmaceuticals, up from $4.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $4.7 million in Q1 2016 to a low of $4.4 million in Q4 2014.
• The 3-year median for Total Debt is $4.5 million (2015), against an average of $4.5 million.
• Across the five-year window, Total Debt advanced 3.92% in 2015 and climbed 3.84% in 2016, its largest moves.
• KalVista Pharmaceuticals' Total Debt stood at $4.4 million in 2014, then climbed by 3.92% to $4.6 million in 2015, then rose by 0.91% to $4.7 million in 2016.
• The last three Total Debt figures came in at $4.7 million (Q1 2016), $4.6 million (Q4 2015), and $4.6 million (Q3 2015), per Business Quant data.